Twynsta_ 40/5 Mg. Twynsta_ 40/10 Mg. Twynsta_ 80/5 Mg. Twynsta_ 80/10 Mg 40/5 mg. 40/10 mg. 80/5 mg. 80/10 mg Tablet
PDF Leaflet Revision Date: 04 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential hypertension.
Dosage (summary)
Adults: 40/5 mg once daily, may titrate to 80/10 mg.
Onset of Action / Duration
Onset: 3 hours, Duration: 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Lithium
- NSAIDs
- CYP3A4 inhibitors
- Aliskiren
Contraindications
- Hypersensitivity
- Severe renal impairment
- Severe hepatic impairment
- Pregnancy
- Lactation
Common side effects
- Dizziness
- Hypotension
- Peripheral edema
- Fatigue
Counselling Points
- Take once daily with or without food.
- Avoid grapefruit juice.
- Monitor blood pressure regularly.
Serious warnings
- Dual blockade of RAAS may increase risk of hypotension and renal impairment.
- Monitor potassium levels.
Important Disclaimer
The Twynsta_ 40/5 Mg. Twynsta_ 40/10 Mg. Twynsta_ 80/5 Mg. Twynsta_ 80/10 Mg 40/5 mg. 40/10 mg. 80/5 mg. 80/10 mg Tablet professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
